DHL Supply Chain, a provider of contract logistics and part of Deutsche Post DHL Group, is expanding its pharmaceutical and medical device distribution network by 40% this year with an investment of $150 million. The company plans for nine new sites by the end of 2019 in order to reach their ultimate goal of bringing critical healthcare products closer to trade partners and patients. The investment includes costs for new buildings and technology, as well as the fit-out and start-up of new or expanded operations.
The expansion brings the total number of pharmaceutical, biotech, and medical device distribution sites to 30. The business is expanding with new market investments in Indianapolis, IN, and Raleigh, NC; multiple new facilities in key campus markets such as Memphis, TN, and South Central, PA, and new sites in California and Virginia.
“This expansion allows DHL Supply Chain to continue to deepen the connections between our customers and the patients they serve,” says Scott Cubbler, President of Life Sciences & Healthcare at DHL Supply Chain. “This most recent expansion also helps us leverage differentiated routes to market, driving even greater efficiency and productivity across the supply chain for our customers.”
These sites, carefully located throughout the U.S., will be fully licensed with temperature-controlled space that supports pharmaceutical storage requirements. The sites will also be designed for packaging and managed transportation for integrated solutions.